Navigation Links
Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Date:1/29/2008

r of 2007, Amicus successfully completed a series of Phase I clinical studies of AT2220 in healthy volunteers. AT2220 is an orally available small-molecule pharmacological chaperone targeting the enzyme deficient in people living with Pompe disease. These studies demonstrated that AT2220 was generally safe and well-tolerated at all doses tested and that there were no drug-related serious adverse events. Amicus expects to report on these data at the ACMG conference in March along with the results of an additional clinical ex vivo response study designed to test the responsiveness of various Pompe mutations to AT2220.

"The data from these Phase 2 trials of Amigal and Plicera are part of an expanding body of scientific and clinical evidence that we are building through rigorous studies to demonstrate that many patients with Fabry, Gaucher and Pompe disease may be successfully switched from ERT to a pharmacological chaperone," noted John Crowley.

Other Protein Folding and Stabilization Programs:

In 2008, Amicus expects to accelerate its investments in research and development to better understand the potential for using pharmacological chaperones to treat a range of human genetic diseases that could benefit from improved protein folding and stabilization.

The company's advanced pre-clinical program in Parkinson's disease, funded in part by a grant from the Michael J. Fox Foundation, will continue with the potential to initiate clinical studies in 2008. In the fourth quarter of 2007, the company announced pre-clinical results which further support a biochemical link between the GCase enzyme and the accumulation of alpha- synuclein, a protein believed to play a key role in Parkinson's disease. Furthermore, in an animal model Amicus showed preliminary pre-clinical results that for the first time demonstrated that administration of a pharmacological chaperone can lead to reduction of alpha-synuclein aggregates in the brain. These results were fir
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
2. Amicus Therapeutics to Host R&D Day
3. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
4. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
5. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
6. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
7. Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
8. Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders
9. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
10. Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors
11. Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... 28, 2015 Increasing its efforts to resolve ... its first three episodes of The GMO TRUTH podcast on ... month, as it continues its mission to discover the truth ... first phase, to “uncover the truth about the GMOs in ... The GMO Truth Podcast is an expansion of the documentary/investigative ...
(Date:2/27/2015)... 2015 Immunovaccine Inc. (“Immunovaccine” or the ... fraudulent press release disseminated this morning by PR Web, ... This press release states that Immunovaccine has entered into ... press release did not originate from Immunovaccine and there ... press release. Please note that all official statements ...
(Date:2/27/2015)... SUMMERLAND, British Columbia , Feb. 27, 2015 ... ), a leader in synthetic biology, today announced it ... Fruits (OSF), the pioneering agricultural company behind the ... non-browning apple. Through the acquisition, Intrexon expands its food ... appetizing and convenient for consumers while providing economic benefit ...
(Date:2/27/2015)... Calif. , Feb. 27, 2015  Pharmacyclics, ... that longer-term toxicology studies for its newly developed ... or RA, have been completed. The results of ... U.S. Food and Drug Administration. The feedback received ... of the ongoing first-in-human study. Additional preclinical work ...
Breaking Biology Technology:The Walk a Mile Project Launches “GMO Truth” Podcast 2Immunovaccine Disclaims Hoax Press Release 2Intrexon to Acquire Okanagan Specialty Fruits 2Intrexon to Acquire Okanagan Specialty Fruits 3Intrexon to Acquire Okanagan Specialty Fruits 4Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3
... , Scientists have invented methods to scout the human ... identical and heavily duplicated. These advances, as reported ... important differences among people in the number and content ... variations partly account for the normal diversity among people. ...
... annual Indiana Life Sciences Summit today, BioCrossroads recognized one ... Ph. D, founder and former chief executive officer of ... of the Year award, a prestigious honor named in ... founded the global orthopedic giant, Biomet, just thirty years ...
... 27 Ardea Biosciences, Inc. (Nasdaq: RDEA ) ... executive officer, will present at the Oppenheimer 21st Annual Healthcare ... present at 10:50 a.m. EDT on Tuesday, November 2, 2010. ... be accessed on the Investor Relations section of Ardea,s website ...
Cached Biology Technology:New methods detect subtleties in human genomes' repetitive landscapes 2New methods detect subtleties in human genomes' repetitive landscapes 3Orthopedics Entrepreneur Named BioCrossroads Watanabe Life Sciences Champion of the Year 2Orthopedics Entrepreneur Named BioCrossroads Watanabe Life Sciences Champion of the Year 3Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference 2
(Date:2/25/2015)... Feb. 25, 2015  ABC Financial Services (ABC), ... the Health and Fitness Industry, today announced enhancements ... MYiCLUBonline.  The latest upgrade includes advances to the ... cardless check-in via Identity One fingerprint biometrics. The ... through interactive displays at the International Health, Racquet ...
(Date:2/24/2015)... 2015 This report analyzes the worldwide markets for ... analytics for the US, Canada , ... Asia-Pacific , Middle East , ... forecasts are provided for the period 2013 through 2020. Also, ... data and analytics are derived from primary and secondary research. ...
(Date:2/24/2015)... YORK , Feb. 24, 2015 This report analyzes ... by the following Segments: Face Biometrics, and Voice Biometrics. The report ... , Japan , Europe , ... & Africa , and Latin America ... 2013 through 2020. Also, a seven-year historic analysis is provided for ...
Breaking Biology News(10 mins):ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16
... from one of his frequent trips to Kibale National Park, ... how infectious diseases spread and evolve in the wild. But ... the U.S., I realized I had a stowaway," says Goldberg, ... of Veterinary Medicine and associate director for research in the ...
... 10 per cent of the UK is left handed ... world. But why exactly someone is left or right handed ... Nottingham,s Professor John Armour and Dr Angus Davison, in collaboration ... genetic determinant, in influencing handedness. The researchers conducted ...
... Avondale, Pa. Stroud Water Research Center welcomes Melinda Daniels, ... a name for herself and her work at the Center. ... by Secretary of Defense Chuck Hagel to serve on the ... Her term begins in December. Moreover, she has secured ...
Cached Biology News:UW scientist sniffs out possible new tick species 2UW scientist sniffs out possible new tick species 3What makes us left or right handed? New study rules out strong genetic factors 2
WNV Core Antibody...
Rad51, N-terminal...
Rabbit polyclonal to WWOX8 ( Abpromise for all tested applications). entrezGeneID: 51741 SwissProtID: Q9NZC7-8...
Goat polyclonal to T7 tag (Agarose) Immunogen: Goats were immunized with MASMTGGQQMG (T7) conjugated to KLH.After multiple immunizations in Freund's adjuvant, serum was collected....
Biology Products: